UBS maintains Huntsman at Neutral, raises price target to $10 from $9

UBS kept its Neutral rating on Huntsman but increased its price target to $10 from $9, an 11.1% rise. The new target is close to the stock's recent close of $9.95. Other analysts' price targets for Huntsman range from $9 to $11.

Original reporting
Published Nov 4, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Huntsman at Neutral, raises price target to $10 from $9 — source image
Decision brief

The 30-second read

$HUNBullishLow
01

Why it matters

The upward revision could attract short‑term buying interest but is unlikely to drive a large move.

02

Market read

A modest analyst target increase provides a small catalyst for Huntsman shares.

03

What to watch

No new operational or financial data accompanies the target change.

Relevance 5/10Novelty 5/10Timing: same-day release

Background

UBS analyst coverage on Huntsman includes recent notes with targets ranging $9‑$11.

Company-level read

Ticker impact

$HUNBullishMedium confidence
Context

UBS raised its price target on Huntsman to $10 from $9, indicating a fresh, positive analyst view.

Expected impact

likely slight upward pressure as investors price in the higher target

Evidence & confidence

Analyst target increase is a new data point that can shift expectations, but the magnitude is small.

Market effects

Minimal impact on the specialty chemicals sector.

Limited to U.S. investors tracking Huntsman.

Low

Counterpoint

Target raise may be modest and already priced in, limiting upside.

Key entities

  • UBS

    Equity research firm issuing the target raise.

  • Huntsman Corp

    Specialty chemicals manufacturer.

Related articles

$HUNMed

KeyBanc raises Huntsman stock price target on merger synergies

KeyBanc raised its price target for Huntsman (NYSE:HUN) to $13, citing merger synergies with OLN and better-than-expected Q3 results. The stock trades at $9.45, with a Fair Value of $13.16. Huntsman reported mixed Q3 earnings, missing EPS estimates but exceeding revenue forecasts. Jefferies initiated coverage with a Buy rating and $12 target. The company faces rising input costs but aims for $100M EBITDA improvement in 2026.

$HUNMed

Huntsman Q3 Earnings Call Highlights

Huntsman (HUN) reported Q3 earnings, noting seasonal slowing and higher raw-material costs in North American MDI markets. The company expects 2027 industry MDI growth to be flat to 2% and sees growth opportunities in advanced materials and automotive applications. Huntsman generated $82M in free cash flow in Q3 and anticipates substantial cash inflow in Q4. Europe remains challenging due to high energy costs, while China's market shows stability.

$HUNMed

Huntsman Corp (HUN) (Q3 2026) Earnings Call Highlights: $100 Million EBITDA Boost

Huntsman Corp (HUN) reported a $100M EBITDA boost in Q3 2026, with CEO Peter Huntsman expressing confidence in meeting $300M synergy targets from the Olin merger. He discussed market positioning, cost management, and growth expectations, including GDP-plus growth in Advanced Materials through 2027. The company expects to cover its dividend and capex with operating cash flow, despite minimal cash flow in the first nine months.

$HUNMedAI 8/10

Huntsman: Q3 Earnings Snapshot

Huntsman Corp. (HUN) reported a Q3 loss of $18M, or 10 cents per share, missing analyst expectations of 7 cents per share. Adjusted earnings were 4 cents per share. Revenue was $1.72B, exceeding forecasts of $1.6B.